TOMI Environmental Solutions, Inc. reported accelerating adoption of its SteraMist platform on June 23, 2026, as healthcare providers, emergency response agencies, and public health organizations increase spending on biosecurity preparedness. The company attributes the rising commercial demand to a growing number of pathogen outbreaks, including Ebola, measles, and norovirus, which have reinforced the necessity for permanent operational readiness rather than temporary responses. Governments and healthcare systems are investing heavily in preparedness programs to improve response capabilities before future outbreaks occur, creating a significant long-term opportunity for advanced decontamination technologies.

Deployments of SteraMist have expanded internationally, with an established partner broadening usage across emergency medical transport and healthcare facilities to support high-consequence pathogen readiness. In the United States, healthcare systems and federally supported preparedness programs are increasing adoption to strengthen environmental decontamination protocols. The company believes that scalable environmental disinfection solutions are becoming an increasingly important component of operational readiness for critical infrastructure operators and transportation networks.

"We continue to see growing recognition that preparedness cannot begin after an outbreak occurs," said Dr. Halden Shane, CEO of TOMI Environmental Solutions. "Organizations are investing ahead of potential threats, and they are looking for proven technologies that can be deployed rapidly, effectively, and at scale. We believe SteraMist is uniquely positioned to address that need."

Market Drivers and Financial Impact

The global infection prevention and decontamination market is expanding due to increasing awareness of healthcare-associated infections (HAIs), emerging pathogen risks, and stricter regulatory requirements. In the United States alone, HAIs impact approximately one in twenty-five hospital patients and are estimated to contribute tens of billions of dollars annually in healthcare costs. TOMI expects these industry trends to continue supporting commercial momentum throughout 2026 and beyond.

Future Technological Integration

Looking ahead, TOMI sees opportunities to expand deployment through automation, robotics, and emerging autonomous delivery systems. These technologies aim to enhance large-scale decontamination capabilities in hospitals, transportation hubs, public facilities, and emergency response scenarios. The company emphasizes that the ability to disinfect at scale will become increasingly important for protecting large facilities and complex environments quickly and efficiently.

TOMI Environmental Solutions, Inc. has announced a major step toward achieving NSF certification for its patented SteraMist ionized Hydrogen Peroxide (iHP) technology, a milestone that could accelerate adoption across pharmaceutical manufacturing, biotechnology, cleanroom, biosafety, and laboratory markets worldwide. The company, a global leader in disinfection and decontamination solutions, stated that NSF International is a global, independent organization that develops public health standards and certifications to protect food, water, consumer products, and the environment. This initiative targets some of the fastest-growing sectors of the global contamination-control industry, including pharmaceutical production facilities, vaccine manufacturing operations, cell and gene therapy laboratories, biomedical research institutions, biosafety cabinets, and high-containment environments.

Certification Process and Strategic Partnership

As part of the certification process, TOMI and its strategic partner, Total Clean Air (TCA), presented before the NSF Joint Committee on Biosafety Cabinets on June 17, 2026. The presentation is designed to establish the framework for formal validation studies to test the SteraMist iHP decontamination protocol across multiple types of biosafety cabinets (BSCs), which could ultimately lead to NSF certification of TOMI's SteraMist decontamination protocol. Management believes NSF certification would provide independent third-party validation of SteraMist's effectiveness, repeatability, and material compatibility, helping remove a significant barrier to adoption for highly regulated industries where validated decontamination procedures are critical.

Market Opportunity and Industry Trends

The global life sciences industry continues to invest heavily in contamination-control technologies driven by growth in biologics manufacturing, cell and gene therapy production, vaccine development, advanced research, and regulatory compliance requirements. TOMI believes SteraMist's rapid cycle times, broad-spectrum efficacy, and material compatibility position the technology to capitalize on these long-term industry trends. The company estimates that these markets represent billions of dollars in annual spending on contamination prevention, validation, and facility operations. Certification could help streamline purchasing decisions for facility operators, biosafety officers, pharmaceutical manufacturers, and equipment providers by providing an independent industry-recognized validation standard.

Leadership Commentary

"Achieving NSF certification has the potential to be a transformative milestone for TOMI," said Elissa (E.J.) Shane, COO of TOMI Environmental Solutions. "This process is about much more than biosafety cabinets. It is about positioning SteraMist for broader adoption across pharmaceutical manufacturing, biotechnology, research laboratories, cleanrooms, and other mission-critical environments where contamination control is essential." Shane added that the objective is to establish SteraMist as a trusted decontamination solution across the life sciences ecosystem, representing an important step toward expanding the addressable market, accelerating adoption, and creating new recurring revenue opportunities across multiple high-value industry verticals.

Key Metrics and Details